[HTML][HTML] Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH
J Oldenburg, R Klamroth, F Langer, M Albisetti… - …, 2021 - thieme-connect.com
J Oldenburg, R Klamroth, F Langer, M Albisetti, C Von Auer, C Ay, W Korte, RE Scharf…
Hämostaseologie, 2021•thieme-connect.comThe COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of
atypically located thromboses following vaccination with the AstraZeneca COVID-19
vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance
statements on the recognition, diagnosis, and treatment of this rare complication. It shares
pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to
as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
atypically located thromboses following vaccination with the AstraZeneca COVID-19
vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance
statements on the recognition, diagnosis, and treatment of this rare complication. It shares
pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to
as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
Thieme Connect